About TG Therapeutics, Inc.
https://www.tgtherapeutics.comTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
CEO
Michael S. Weiss
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-04-30 | Reverse | 4:225 |
| 2011-07-19 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 168
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
PICTET ASSET MANAGEMENT HOLDING SA
Shares:1.61M
Value:$47.55M
PICTET ASSET MANAGEMENT LTD
Shares:1.6M
Value:$47.3M
BLACKROCK FUND ADVISORS
Shares:1.18M
Value:$34.81M
Summary
Showing Top 3 of 171
About TG Therapeutics, Inc.
https://www.tgtherapeutics.comTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $161.71M ▲ | $104.19M ▲ | $390.89M ▲ | 241.73% ▲ | $2.69 ▲ | $32.69M ▼ |
| Q2-2025 | $141.15M ▲ | $87.37M ▼ | $28.19M ▲ | 19.97% ▲ | $0.19 ▲ | $37.7M ▲ |
| Q1-2025 | $120.86M ▲ | $96.69M ▲ | $5.06M ▼ | 4.19% ▼ | $0.03 ▼ | $12.28M ▼ |
| Q4-2024 | $108.19M ▲ | $62.84M ▲ | $23.33M ▲ | 21.57% ▲ | $0.16 ▲ | $32.58M ▲ |
| Q3-2024 | $83.88M | $62.1M | $3.88M | 4.63% | $0.03 | $15.16M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $131.58M ▼ | $1.03B ▲ | $417.81M ▼ | $607.22M ▲ |
| Q2-2025 | $251.87M ▼ | $702.61M ▲ | $426.18M ▲ | $276.43M ▲ |
| Q1-2025 | $276.24M ▼ | $656.69M ▲ | $419.4M ▲ | $237.29M ▲ |
| Q4-2024 | $311M ▼ | $577.69M ▼ | $355.33M ▼ | $222.36M ▲ |
| Q3-2024 | $341.04M | $586.01M | $393.86M | $192.16M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $390.89M ▲ | $-23.15M ▼ | $46.36M ▲ | $-78.24M ▼ | $-55.03M ▼ | $-23.23M ▼ |
| Q2-2025 | $28.19M ▲ | $7.44M ▲ | $-3.99M ▲ | $-6.44M ▼ | $-3M ▲ | $7.39M ▲ |
| Q1-2025 | $5.06M ▼ | $-28.71M ▼ | $-12.93M ▼ | $-6.1M ▼ | $-47.75M ▼ | $-28.74M ▼ |
| Q4-2024 | $23.33M ▲ | $-25.64M ▼ | $15.79M ▲ | $-6.07M ▼ | $-15.93M ▼ | $-25.66M ▼ |
| Q3-2024 | $3.88M | $-12.21M | $-9.33M | $134.45M | $112.92M | $-12.23M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 License Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $180.00M ▲ | $140.00M ▼ | $160.00M ▲ | $120.00M ▼ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Milestone | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2025 |
|---|---|
 UNITED STATES | $150.00M ▲ |
CEO
Michael S. Weiss
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-04-30 | Reverse | 4:225 |
| 2011-07-19 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 168
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
PICTET ASSET MANAGEMENT HOLDING SA
Shares:1.61M
Value:$47.55M
PICTET ASSET MANAGEMENT LTD
Shares:1.6M
Value:$47.3M
BLACKROCK FUND ADVISORS
Shares:1.18M
Value:$34.81M
Summary
Showing Top 3 of 171